Husam Bakri discusses avian influenza and mycoplasma infection
Published:March 13, 2017
Husam Bakri, Global Technical Expert at Merck, explained his findings on avian influenza in the Middle East and North Africa, as well as economic impact, vaccination, and biosecurity, during IPPE 2017 in Atlanta, USA.
Thank you Dr Bakri for raising an important but lesser discussed issue of H9N2 LPAI.
I have recently done a review of this problem in Asia and Indian subcontinent. It was published in International Hatchery Practice (Volume 31 Number 2 (2017). I would like to share the same with fellow professionals.
Kindly click on the link below.
http://www.positiveaction.info/digital/IHP/2017/IHP_31_2/pdf/IHP_31_2.pdf
and go to page 11/36.
Regards
Dr. Husam Bakri, very good information. In India also we are finding a lot of cases of HP and LP IE AI. We are not having vaccine for AI. So we are losing heavily in layers and breeders. Any concrete steps for AI?
Dear Dr. Zade, First, thank you for your email. Actually in our area AI H9N2 vaccine did a very good job to reduce the losses from AI H9N2, for sure with good biosecurity, good farm management with good vaccination program against other diseases like ND and IB virulent strains.
We had very good experience when the vaccine is not available in the market farmers were using good vaccination program against ND which they could reduce the losses from AI H9N2. Regarding HPAIV there is a study done by South Poultry Research Laboratory USDA/ARS, Athens, GA, USA. Showing when there is mNDV has replication advantage it is able to interfere with a second virus infection, most likely by inducing an antiviral state due to the activation of innate immune mechanisms that prevent host cells from being infected by a second virus.
You can see the full study on World Poultry SEP. 2014.
All the best and hope I was able to answer your question.
Thank you both (Dr. Bakri/Dr. Belwal) for sharing your views.
My question (to Dr. Lalit bewal) is:
Up to what extent should this suggested vaccine (H9N2) ensure protection against challenges from the field viruses?
Will this vaccine provide protection against different strains of the same subtype (H9N2) ?
Thank you
Dr. Jignesh Barot
Doctor Husam, thank you very much for this information. Here in Nigeria we have had a couple of avian influenza outbreaks , Although, many efforts are being undertaken by both government and stake holders to curtail this disease. With better stock management, bio-security, improved nutrition and superb breeder stocks ,there are hopes that the disease would be controlled within Nigeria.
Up to what extent should this suggested vaccine (H9N2) ensure protection against challenges from the field viruses?
Will this vaccine provide protection against different strains of the same subtype (H9N2) ?
Dear Dr. Bardot, First thank you for your comments. From our field experience, over 18 years using this vaccines, yes, it gives very good protection against H9N2, which is always challenging the breeders and layers when the production is going to the peak. No H9N2 vaccine will not give cross protection against other AI serotype.
Dr. Bakri,
Thank you for your reply.
How old is the seed H9N2 virus used for production of this inactivated vaccine?
Will this vaccine provide protection If there is one or more point mutation in H9N2 subtype virus ?
Would please share challenge studies with currently isolated H9N2 strains?
Thanks & Regards,,,,,,
Dr. Jignesh Barot
Dear Dr. Bardot,
1- It has been isolated on 1998 from Middle East and produced as vaccine 1999.
2- yes for the following reasons :
- from our field experience results from the vaccine till now gave great 90-95 of breeders and layers using the vaccine .
- last few year I have reisolted the virus from 3 differences countries and we found out that the filed virus still same vaccine virus.
All the best
Bakri
.jpg&w=3840&q=75)
.jpg&w=3840&q=75)
.jpg&w=3840&q=75)
